Bulls, Bears: The State of Cancer Immunotherapy in the Public Markets

This is Part II of our special report on the state of immunotherapy in the public markets. This report looks at promising anticancer immunotherapy technologies, and the major issues in bringing these technologies to the general public.

Read more »

Dendreon: Anticancer Immunotherapy, Reimbursement, and New Promises

This is Part I of our special report on the state of immunotherapy in the public markets. This report looks at promising anticancer immunotherapy technologies, and the major issues in bringing these technologies to the general public.

Read more »

Oncology Drugs Experience Sales Slowdown In U.S.

Cancer drug sales are slowing down in the U.S., Reuters reported Monday.

Read more »

IMUC: Immunotherapy On Multiple Fronts

In a study of 19 patients with glioblastoma, progression-free survival increased from 6 months to 19 months.

Read more »

Cancer Vaccines: Investing Opportunities Beyond Dendreon

Despite the setbacks and pitfalls experienced by early-stage pioneers in the cancer immunotherapy / therapeutic cancer vaccine space, recent advancements and study results are encouraging.

Read more »

Dendreon to Build $70 Million Plant Near Atlanta

The 160,000 square-foot facility could bring at least 300 jobs to Georgia.

Read more »

Provenge Extends Life of Prostate Cancer Patients, Study Finds

Researchers found that Dendreon’s immunotherapy drug Provenge prolonged the lives of advanced prostate cancer patients by an average of 4.1 months compared to a placebo.

Read more »